Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Short term Debt (2016 - 2021)

ImmunityBio (IBRX) has disclosed Short term Debt for 8 consecutive years, with $8.7 million as the latest value for Q3 2021.

  • Quarterly Short term Debt rose 541.37% to $8.7 million in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $8.7 million through Sep 2021, up 541.37% year-over-year, with the annual reading at $14.8 million for FY2020, 2953.09% up from the prior year.
  • Short term Debt for Q3 2021 was $8.7 million at ImmunityBio, down from $16.7 million in the prior quarter.
  • The five-year high for Short term Debt was $17.8 million in Q1 2021, with the low at $486000.0 in Q4 2019.
  • Average Short term Debt over 5 years is $4.5 million, with a median of $2.1 million recorded in 2017.
  • The sharpest move saw Short term Debt crashed 71.34% in 2019, then skyrocketed 2953.09% in 2020.
  • Over 5 years, Short term Debt stood at $2.4 million in 2017, then decreased by 28.23% to $1.7 million in 2018, then plummeted by 71.34% to $486000.0 in 2019, then surged by 2953.09% to $14.8 million in 2020, then plummeted by 41.39% to $8.7 million in 2021.
  • According to Business Quant data, Short term Debt over the past three periods came in at $8.7 million, $16.7 million, and $17.8 million for Q3 2021, Q2 2021, and Q1 2021 respectively.